



Ref: FOIA Reference 2021/22-225

Date: 20th September 2021

Email foi@uhn.nhs.uk

Dear

I am writing to acknowledge receipt of your email dated 19th July 2021 requesting information under the Freedom of Information Act (2000) regarding Chronic Kidney Disease.

On 20th July 2021 we contacted you via email as we required the following clarification:

Did you mean treated with the drugs in Q1 for the conditions in Q2?

On 31st August 2021 you replied via email with:

'For Q2 please give us the overall patients treated regardless to the drugs mentioned in Q1 (overall number).'

I can neither confirm nor deny whether the information you have requested is held by the Trust in its entirety. This is because the information requested in questions 2 (partial) and 3 is not held centrally, but may be recorded in individual health records. In order to confirm whether this information is held we would therefore have to individually access all health records within the Trust and extract the information where it is present. We therefore estimate that complying with your request is exempt under section 12 of the FOI Act: *cost of compliance is excessive*. The section 12 exemption applies when it is estimated a request will take in excess of 18 hours to complete. We estimate that accessing and reviewing all health records and then extracting relevant information would take longer than the 18 hours allowed for. In addition to the section 12 exemption the Trust is also applying section 14 (1) exemption: *oppressive burden on the authority*

Under section 16 of the FOI Act we are required to provide requestors with advice and assistance where possible. We would therefore like to advise you that if your request is shortened to just the questions that we are able to comply within the 18 hour time frame. In order to avoid delay to your response we have provided this below.

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 I am researching the incidence and treatment of Chronic Kidney Disease. I would greatly appreciate if you could answer the following questions.

Q1. How many patients have been treated in the last 6 months (for any disease) with the following products?

- **Aranesp & Aranesp SureClick (darbepoetin alpha)**
- **Eporex (epoetin alba)**

- **NeoRecormon (epoetin beta)**
- **Retacrit (epoetin zeta)**
- **Mircera (methoxy polyethylene glycol-epoetin beta)**
- **Ferinject (ferric carboxymaltose injection/infusion)**
- **Diafer (ferric derisomaltose injection)**
- **Monofer (ferric derisomaltose injection)**
- **Cosmofer (iron dextran injection)**
- **Venofer (iron sucrose injection)**

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

Data shown for March 21 – August 21 inclusive. Please note ward stock is not booked to patient so cannot be included.

Aranesp & Aranesp SureClick (darbepoetin alpha)	587
Epex (epoetin alba)	<5
Ferinject (ferric carboxymaltose injection/infusion)	87
Monofer (ferric derisomaltose injection)	521
NeoRecormon (epoetin beta)	<5

Q2 In the past 6 months could you please state the number of patients treated for the following conditions:

- **Chronic kidney disease (ICD10 code – N.18)**
- **Chronic kidney disease - Stages 4 & 5 (ICD10 codes – N.18.3 & N.18.4 & N.18.5)**
- **Acquired cystic kidney disease (ICD10 code N28.1)**
- **Chronic kidney disease – new patients (excluding previously treated patients)**
- **Acquired cystic kidney disease - new patients (excluding previously treated patients)**

A2 See below:

Chronic kidney disease (ICD10 code – N.18)	circa 1000
Chronic kidney disease - Stages 4 & 5 (ICD10 codes – N.18.3 & N.18.4 & N.18.5)	Section 12 exemption as detailed above
Acquired cystic kidney disease (ICD10 code N28.1) -	Section 12 exemption as detailed above
Chronic kidney disease – new patients (excluding previously treated patients) –	Around 38
Acquired cystic kidney disease - new patients (excluding previously treated patients)	Section 12 exemption as detailed above

Q3 Please indicate the number of patients treated in the last 6 months for chronic kidney disease ONLY with each of the following products:

- Aranesp & Aranesp SureClick (darbepoetin alpha)
- Eprex (epoetin alfa)
- NeoRecormon (epoetin beta)
- Retacrit (epoetin zeta)
- Mircera (methoxy polyethylene glycol-epoetin beta)
- Ferinject (ferric carboxymaltose injection/infusion)
- Diafer (ferric derisomaltose injection)
- Monofer (ferric derisomaltose injection)
- Cosmofer (iron dextran injection)
- Venofer (iron sucrose injection)

A3 Section 12 exemption as detailed above

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.


Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,

A handwritten signature in black ink on a light-colored background. The signature reads "Jean Lehnert" in a cursive script.

Jean Lehnert
Data, Security & Protection Manager